Compare Abeona Therapeutics Inc (ABEO) vs Alexandria Real Estate Equities Inc (ARE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Alexandria Real Estate Equities Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Alexandria Real Estate Equities Inc trades at $48.37 (market cap $8.61B). The key difference: Alexandria Real Estate Equities Inc is far larger — about 23.1× Abeona Therapeutics Inc's market cap, and Alexandria Real Estate Equities Inc pays a 5.83% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ARE | |
|---|---|---|
Market Cap | $373.32M | $8.61B |
Sector | Health | Real Estate |
52-Week High | $7.23 | $87.45 |
52-Week Low | $4.17 | $40.41 |
Enterprise Value | $228.22M | $21.07B |
Dividend Yield | — | 5.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Alexandria Real Estate Equities (ARE) trades at $49.41, down 6.03% over 24 hours amid bearish technical signals and mixed fundamentals. The stock shows negative profitability with -37.09% net income margin and -6.43% ROE, though valuation metrics like P/B of 0.55 suggest potential undervaluation. Recent earnings have been inconsistent with two misses in the last four quarters. The company maintains strong operational cash flow of $1.41B and declared a $0.72 dividend for Q2 2026.
ARE faces headwinds from declining occupancy guidance and net losses, but analyst consensus remains cautiously optimistic with a $51 price target and 37.5% buy ratings. Key risks include high debt levels (40.79% debt-to-asset ratio) and uneven demand in life science real estate. The stock's current position near support at $49 offers potential for recovery if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →
